Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR1F | P30939 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238843 | 0.86 | HTR6 (0.57) | HTR6PTGDR2HTR1AHTR1DHTR1B | |
| SCHEMBL5237874 | 0.86 | HTR6 (0.55) | HTR6PTGDR2HTR1AHTR1DHTR1B | |
| SCHEMBL5239230 | 0.86 | HTR6 (0.67) | HTR6PTGDR2HTR1AHTR1DHTR1B | |
| SCHEMBL5236597 | 0.86 | HTR6 (0.76) | HTR6PTGDR2HTR1AHTR1DHTR1B | |
| SCHEMBL5238805 | 0.86 | HTR6 (0.72) | HTR6PTGDR2HTR1AHTR1DHTR1B | |
| SCHEMBL5235317 | 0.84 | HTR6 (0.61) | HTR6PTGDR2HTR1AHTR1DHTR1B | |
| SCHEMBL5236964 | 0.84 | HTR6 (0.52) | HTR6PTGDR2HTR7 | |
| SCHEMBL5238837 | 0.82 | HTR6 (0.59) | HTR6PTGDR2HTR7 | |
| SCHEMBL5239159 | 0.81 | HTR6 (0.61) | HTR6PTGDR2 | |
| SCHEMBL5238266 | 0.79 | HTR6 (0.62) | HTR6PTGDR2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648904-B1 | N-SULFONYLHETEROCYCLOPYRROLYLALKYLAMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-08-22 | — | — | EP | claimed |
| JP-2007500701-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-7041695-B2 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-05-09 | — | — | US | claimed |
| EP-1648904-A1 | N-SULFONYLHETEROCYCLOPYRROLYLALKYLAMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-04-26 | — | — | EP | claimed |
| US-20050038088-A1 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-02-17 | — | — | US | claimed |
| WO-2005012311-A1 | N-SULFONYLHETEROCYCLOPYRROLYLALKYLAMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-02-10 | — | — | WO | claimed |
| EP-1648904-B1 | N-SULFONYLHETEROCYCLOPYRROLYLALKYLAMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7220756-B2 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060160878-A1 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-07-20 | — | — | US | disclosed |
| US-7041695-B2 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1648904-A1 | N-SULFONYLHETEROCYCLOPYRROLYLALKYLAMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050038088-A1 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012311-A1 | N-SULFONYLHETEROCYCLOPYRROLYLALKYLAMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038088-A1 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885PTGDR2 338/4885HTR1A 3/4885 |
| US-20060160878-A1 | N-sulfonylheterocyclopyrrolyl-alkylamine compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885PTGDR2 338/4885HTR1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.